
Graham L Radford-Smith

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3376067/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Microbiota links to neural dynamics supporting threat processing. Human Brain Mapping, 2022, 43, 733-749.	3.6	12
2	Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials. The Lancet Gastroenterology and Hepatology, 2022, 7, 17-27.	8.1	44
3	Dietary intake of patients with inflammatory bowel disease aligns poorly with traditional Mediterranean diet principles. Nutrition and Dietetics, 2022, 79, 229-237.	1.8	5
4	Markers of Systemic Inflammation in Acute Attacks of Ulcerative Colitis: What Level of C-reactive Protein Constitutes Severe Colitis?. Journal of Crohn's and Colitis, 2022, 16, 1089-1096.	1.3	14
5	Nudix Hydrolase 15 lossâ€ofâ€function variants in an Australian Inflammatory Bowel Disease population. Internal Medicine Journal, 2022, , .	0.8	3
6	Multicenter Study of Drain Fluid Amylase as a Biomarker for the Detection of Anastomotic Leakage After Ileal Pouch Surgery Without a Diverting Ileostomy. Diseases of the Colon and Rectum, 2022, 65, 1335-1341.	1.3	1
7	Editorial: is olderâ€onset ulcerative colitis more severe or less aggressively managed?. Alimentary Pharmacology and Therapeutics, 2022, 55, 1350-1351.	3.7	1
8	Headâ€ŧoâ€head trials in inflammatory bowel disease. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 18-19.	2.8	0
9	Prospective randomised controlled trial of adults with perianal fistulising Crohn's disease and optimised therapeutic infliximab levels: PROACTIVE trial study protocol. BMJ Open, 2021, 11, e043921.	1.9	4
10	Systematic Review and Meta-Analysis of Inflammatory Bowel Disease Adverse Events with Anti-Interleukin 17A Agents and Tumor Necrosis Factor Inhibitors in Rheumatic Disease and Skin Psoriasis. Rheumatology and Therapy, 2021, 8, 1603-1616.	2.3	1
11	lleal Pouch-Anal Anastomosis for Ulcerative Colitis: An Australian Institution's Experience. Annals of Coloproctology, 2021, 37, 318-325.	2.0	10
12	Letter: hidden costs in healthcare use for incident and prevalent Crohn's disease and ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2021, 53, 368-369.	3.7	0
13	Anti-TNF Therapy in Pregnant Women With Inflammatory Bowel Disease: Effects of Therapeutic Strategies on Disease Behavior and Birth Outcomes. Inflammatory Bowel Diseases, 2020, 26, 93-102.	1.9	20
14	Shortâ€ŧerm colectomy is avoided in over half of regional patients failing medical therapy for acute severe ulcerative colitis with coâ€ordinated transfer and tertiary care. Internal Medicine Journal, 2020, 50, 823-829.	0.8	3
15	Level of UV Exposure, Skin Type, and Age Are More Important than Thiopurine Use for Keratinocyte Carcinoma Development in IBD Patients. Digestive Diseases and Sciences, 2020, 65, 1172-1179.	2.3	5
16	A validated risk stratification tool for detecting highâ€risk small bowel Crohn's disease. Alimentary Pharmacology and Therapeutics, 2020, 51, 281-290.	3.7	3
17	Airway Mucus Hyperconcentration in Non–Cystic Fibrosis Bronchiectasis. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 661-670.	5.6	64
18	Associations of NOD2 polymorphisms with Erysipelotrichaceae in stool of in healthy first degree relatives of Crohn's disease subjects. BMC Medical Genetics, 2020, 21, 204.	2.1	11

#	Article	IF	CITATIONS
19	Editorial: obesity management and IBD—weight loss reduces IBD risk. Alimentary Pharmacology and Therapeutics, 2020, 52, 731-732.	3.7	1
20	Telehealth in inflammatory bowel disease. Internal Medicine Journal, 2020, , .	0.8	4
21	Crohn's Colitis Care (CCCare): bespoke cloud-based clinical management software for inflammatory bowel disease. Scandinavian Journal of Gastroenterology, 2020, 55, 1419-1426.	1.5	11
22	Multitrait analysis of glaucoma identifies new risk loci and enables polygenic prediction of disease susceptibility and progression. Nature Genetics, 2020, 52, 160-166.	21.4	192
23	Genome-wide association meta-analyses combining multiple risk phenotypes provide insights into the genetic architecture of cutaneous melanoma susceptibility. Nature Genetics, 2020, 52, 494-504.	21.4	138
24	Randomized, Placebo Controlled Trial of Experimental Hookworm Infection for Improving Gluten Tolerance in Celiac Disease. Clinical and Translational Gastroenterology, 2020, 11, e00274.	2.5	21
25	Altered Expression of Angiotensinogen and Mediators of Angiogenesis in Ileal Crohn's Disease. Journal of Gastrointestinal and Liver Diseases, 2020, 25, 39-48.	0.9	8
26	Crohn's disease is facilitated by a disturbance of programmed deathâ€i ligand 2 on blood dendritic cells. Clinical and Translational Immunology, 2019, 8, e01071.	3.8	12
27	Food avoidance in outpatients with Inflammatory Bowel Disease – Who, what and why. Clinical Nutrition ESPEN, 2019, 31, 10-16.	1.2	28
28	Evaluating a risk assessment tool to improve triaging of patients to colonoscopies. Internal Medicine Journal, 2019, 49, 1292-1299.	0.8	2
29	Co-existence of Network Architectures Supporting the Human Gut Microbiome. IScience, 2019, 22, 380-391.	4.1	22
30	Systematic Review and Meta-analysis: Optimal Salvage Therapy in Acute Severe Ulcerative Colitis. Inflammatory Bowel Diseases, 2019, 25, 1169-1186.	1.9	63
31	Drain fluid amylase as a sensitive biomarker for the early detection of anastomotic leakage in ileal pouch surgery. Colorectal Disease, 2019, 21, 460-464.	1.4	13
32	Thiopurine Therapy in Inflammatory Bowel Diseases: Making New Friends Should Not Mean Losing Old Ones. Gastroenterology, 2019, 156, 11-14.	1.3	27
33	<i>IL23R</i> -Protective Coding Variant Promotes Beneficial Bacteria and Diversity in the Ileal Microbiome in Healthy Individuals Without Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2019, 13, 451-461.	1.3	23
34	Detectable Laboratory Abnormality Is Present up to 12 Months Prior to Diagnosis in Patients with Crohn's Disease. Digestive Diseases and Sciences, 2019, 64, 503-517.	2.3	13
35	Anti-TNF Therapeutic Drug Monitoring in Postoperative Crohn's Disease. Journal of Crohn's and Colitis, 2018, 12, 653-661.	1.3	22
36	Predicting response after infliximab salvage in acute severe ulcerative colitis. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 1347-1352.	2.8	37

#	Article	IF	CITATIONS
37	Editorial: first among Equals—not for either infliximab or adalimumab in Crohn's disease—yet. Alimentary Pharmacology and Therapeutics, 2018, 47, 1225-1226.	3.7	0
38	Protective effects of <i>Helicobacter pylori</i> for IBD are related to the <i>cagA-</i> positive strain. Gut, 2018, 67, 393-394.	12.1	19
39	The effect of pre-admission immunosuppression on colectomy rates in acute severe ulcerative colitis. Therapeutic Advances in Gastroenterology, 2018, 11, 175628481880978.	3.2	6
40	NLRP1 restricts butyrate producing commensals to exacerbate inflammatory bowel disease. Nature Communications, 2018, 9, 3728.	12.8	81
41	Nonsynonymous Polymorphism in Guanine Monophosphate Synthetase Is a Risk Factor for Unfavorable Thiopurine Metabolite Ratios in Patients With Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2018, 24, 2606-2612.	1.9	4
42	Genome-wide association study of intraocular pressure uncovers new pathways to glaucoma. Nature Genetics, 2018, 50, 1067-1071.	21.4	152
43	Development and evaluation of a risk assessment tool to improve clinical triage accuracy for colonoscopic investigations. BMC Cancer, 2018, 18, 229.	2.6	3
44	Entyvio lengthen dose-interval study: lengthening vedolizumab dose interval and the risk of clinical relapse in inflammatory bowel disease. European Journal of Gastroenterology and Hepatology, 2018, 30, 735-740.	1.6	10
45	Chronic cigarette smoke exposure induces systemic hypoxia that drives intestinal dysfunction. JCI Insight, 2018, 3, .	5.0	103
46	Regulation of IL-12p40 by HIF controls Th1/Th17 responses to prevent mucosal inflammation. Mucosal Immunology, 2017, 10, 1224-1236.	6.0	26
47	Editorial: relative efficacy of infliximab and adalimumab in Crohn's disease in an Australian and New Zealand cohort – authors' reply. Alimentary Pharmacology and Therapeutics, 2017, 45, 856-857.	3.7	0
48	Efficacy of Rectal Tacrolimus for Induction Therapy in Patients With Resistant Ulcerative Proctitis. Clinical Gastroenterology and Hepatology, 2017, 15, 1248-1255.	4.4	53
49	Infliximab vs. adalimumab in Crohn's disease: results from 327 patients in an Australian and New Zealand observational cohort study. Alimentary Pharmacology and Therapeutics, 2017, 45, 542-552.	3.7	37
50	Serologic antibodies in relation to outcome in postoperative Crohn's disease. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 1195-1203.	2.8	21
51	Review article: consensus statements on therapeutic drug monitoring of antiâ€ŧumour necrosis factor therapy in inflammatory bowel diseases. Alimentary Pharmacology and Therapeutics, 2017, 46, 1037-1053.	3.7	225
52	UV Exposure and Skin Type are More Important than Thiopurine Exposure for Non-Melanoma Skin Cancer Risk in IBD. Gastroenterology, 2017, 152, S576.	1.3	2
53	Regulation of IL-12P40 by HIF Controls TH1/TH17 Responses to Prevent Mucosal Inflammation. Gastroenterology, 2017, 152, S567-S568.	1.3	0
54	Editorial: faecal microbiota transplantation for ulcerative colitis—not quite there yet?. Alimentary Pharmacology and Therapeutics, 2017, 46, 630-631.	3.7	2

#	Article	IF	CITATIONS
55	Performance of risk prediction for inflammatory bowel disease based on genotyping platform and genomic risk score method. BMC Medical Genetics, 2017, 18, 94.	2.1	36
56	A rolling phenotype in Crohn's disease. PLoS ONE, 2017, 12, e0174954.	2.5	9
57	Sa1964 Weight-Based Dosing of Thiopurines and 6-TGN Concentrations in an Adult Cohort of Patients With Inflammatory Bowel Disease. Gastroenterology, 2016, 150, S418.	1.3	0
58	633 The Relative Abundances of Dorea and Faecalibacterium spp. in the Mucosa Associated Microbiome of Newly Diagnosed Children With Crohn's Disease Are Differentially Affected by Exclusive Enteral Nutrition. Gastroenterology, 2016, 150, S132-S133.	1.3	3
59	A Method to Exploit the Structure of Genetic Ancestry Space to Enhance Case-Control Studies. American Journal of Human Genetics, 2016, 98, 857-868.	6.2	21
60	Concentrations of Adalimumab and Infliximab in Mothers andÂNewborns, and Effects on Infection. Gastroenterology, 2016, 151, 110-119.	1.3	259
61	A Pleiotropic Missense Variant in SLC39A8 Is Associated With Crohn's Disease and Human Gut Microbiome Composition. Gastroenterology, 2016, 151, 724-732.	1.3	109
62	Review article: acute severe ulcerative colitis – evidenceâ€based consensus statements. Alimentary Pharmacology and Therapeutics, 2016, 44, 127-144.	3.7	63
63	High Vitamin D–Binding Protein Concentration, Low Albumin, and Mode of Remission Predict Relapse in Crohn's Disease. Inflammatory Bowel Diseases, 2016, 22, 2456-2464.	1.9	26
64	Sa1924 Colectomy Free Survival in Patients With Acute Severe Ulcerative Colitis (ASUC): Analysis of Outcomes Based on Presentation to a Regional Hospital Versus a Metropolitan Hospital. Gastroenterology, 2016, 150, S405.	1.3	1
65	312 The First Validated Post-Operative Endoscopic Crohns Disease Index: The POCER Index. Identification of Key Endoscopic Prognostic Factors. Gastroenterology, 2016, 150, S72.	1.3	8
66	Sa1923 Oral Corticosteroid Use at Time of Admission Is Associated With an Increased Late Colectomy Rate in Patients With Acute Severe Ulcerative Colitis (ASUC). Gastroenterology, 2016, 150, S404-S405.	1.3	0
67	Sa1884 Risk Factors Predicting Recurrent Ileal Resections in Patients with Crohn's Disease. Gastroenterology, 2016, 150, S391-S392.	1.3	0
68	Clinical Features and HLA Association of 5-Aminosalicylate (5-ASA)-induced Nephrotoxicity in Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2016, 10, 149-158.	1.3	85
69	Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study. Lancet, The, 2016, 387, 156-167.	13.7	607
70	Dysregulation of innate immunity in ulcerative colitis patients who fail anti-tumor necrosis factor therapy. World Journal of Gastroenterology, 2016, 22, 9104.	3.3	20
71	Efficacy of thiopurines and adalimumab in preventing Crohn's disease recurrence in highâ€risk patients – a POCER study analysis. Alimentary Pharmacology and Therapeutics, 2015, 42, 867-879.	3.7	115
72	Accurate Imputation-Based Screening of Cln368Ter Myocilin Variant in Primary Open-Angle Glaucoma. , 2015, 56, 5087.		17

#	Article	IF	CITATIONS
73	Effect of Intestinal Resection on Quality of Life in Crohn's Disease. Journal of Crohn's and Colitis, 2015, 9, 452-462.	1.3	30
74	Crohn's disease management after intestinal resection: a randomised trial. Lancet, The, 2015, 385, 1406-1417.	13.7	475
75	Genome-wide meta-analysis identifies five new susceptibility loci for cutaneous malignant melanoma. Nature Genetics, 2015, 47, 987-995.	21.4	218
76	Response to Magro et al American Journal of Gastroenterology, 2015, 110, 931-932.	0.4	0
77	Smoking behaviour modifies <i>IL23r</i> â€associated disease risk in patients with Crohn's disease. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 299-307.	2.8	18
78	Estimation and partitioning of (co)heritability of inflammatory bowel disease from GWAS and immunochip data. Human Molecular Genetics, 2014, 23, 4710-4720.	2.9	110
79	The Effect on Melanoma Risk of Genes Previously Associated With Telomere Length. Journal of the National Cancer Institute, 2014, 106, .	6.3	109
80	Clinical pharmacology of <scp>AMG</scp> 181, a gutâ€specific human antiâ€Î± ₄ β ₇ monoclonal antibody, for treating inflammatory bowel diseases. British Journal of Clinical Pharmacology, 2014, 78, 1315-1333.	2.4	32
81	Selenoprotein S is a marker but not a regulator of endoplasmic reticulum stress in intestinal epithelial cells. Free Radical Biology and Medicine, 2014, 67, 265-277.	2.9	34
82	Advances in IBD genetics. Nature Reviews Gastroenterology and Hepatology, 2014, 11, 372-385.	17.8	114
83	HLA-DQA1–HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants. Nature Genetics, 2014, 46, 1131-1134.	21.4	165
84	PACSIN2 Does Not Influence Thiopurine-Related Toxicity In Patients With Inflammatory Bowel Disease. American Journal of Gastroenterology, 2014, 109, 925-927.	0.4	7
85	Common variants near ABCA1, AFAP1 and GMDS confer risk of primary open-angle glaucoma. Nature Genetics, 2014, 46, 1120-1125.	21.4	186
86	Perspectives of paediatric and adult gastroenterologists on transfer and transition care of adolescents with inflammatory bowel disease. Internal Medicine Journal, 2014, 44, 490-496.	0.8	47
87	Implementing guidelines on the prevention of opportunistic infections in inflammatory bowel disease. Journal of Crohn's and Colitis, 2013, 7, e449-e456.	1.3	45
88	Su1762 Clinical and Molecular Characterization of Medically Refractory Acute, Severe Colitis: Preliminary Results From the International Inflammatory Bowel Disease Genetics Consortium (IIBDGC) Immunochip Study. Gastroenterology, 2013, 144, S-470.	1.3	6
89	Crohn's disease and smoking: Is it ever too late to quit?. Journal of Crohn's and Colitis, 2013, 7, e665-e671.	1.3	43
90	Surgical outcomes in steroid refractory acute severe ulcerative colitis: the impact of rescue therapy. Colorectal Disease, 2013, 15, 374-379.	1.4	21

#	Article	IF	CITATIONS
91	Deep Resequencing of GWAS Loci Identifies Rare Variants in CARD9, IL23R and RNF186 That Are Associated with Ulcerative Colitis. PLoS Genetics, 2013, 9, e1003723.	3.5	185
92	Hypoxia and Integrin-Mediated Epithelial Restitution during Mucosal Inflammation. Frontiers in Immunology, 2013, 4, 272.	4.8	43
93	Outcomes of salvage therapy for steroid-refractory acute severe ulcerative colitis: ciclosporin vs. infliximab. Alimentary Pharmacology and Therapeutics, 2013, 38, 294-302.	3.7	82
94	Letter: ciclosporin or infliximab in acute ulcerative colitis - still undecided; authors' reply. Alimentary Pharmacology and Therapeutics, 2013, 38, 993-993.	3.7	0
95	Commentary: salvage medical therapy for acute severe colitis - ciclosporin or infliximab? Author's reply. Alimentary Pharmacology and Therapeutics, 2013, 38, 989-989.	3.7	2
96	Genetic Susceptibility in IBD. Inflammatory Bowel Diseases, 2013, 19, 240-245.	1.9	37
97	Granulocyte–Macrophage Colony-Stimulating Factor Autoantibodies. Inflammatory Bowel Diseases, 2013, 19, 1671-1680.	1.9	64
98	Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature, 2012, 491, 119-124.	27.8	4,038
99	Clinical Remission After Stopping Infliximab in Crohn's Disease: Is All That Glitters True Gold?. Gastroenterology, 2012, 142, e17.	1.3	1
100	Inter-observer agreement for Crohn's disease sub-phenotypes using the Montreal Classification: How good are we? A multi-centre Australasian study. Journal of Crohn's and Colitis, 2012, 6, 287-293.	1.3	14
101	1161 Adalimumab Prevents Post-Operative Crohn's Disease Recurrence, and is Superior to Thiopurines: Early Results From the POCER Study. Gastroenterology, 2012, 142, S-212.	1.3	13
102	Common PPARÎ ³ variants C161T and Pro12Ala are not associated with inflammatory bowel disease in an Australian cohort. Journal of Gastrointestinal and Liver Diseases, 2012, 21, 349-55.	0.9	2
103	Smoking Cessation Following the Diagnosis of Crohn's Disease Still Reduces the Rates of Surgery and Complicated Disease. Gastroenterology, 2011, 140, S-429.	1.3	1
104	Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nature Genetics, 2011, 43, 246-252.	21.4	1,201
105	An intestinal epithelial defect conferring ER stress results in inflammation involving both innate and adaptive immunity. Mucosal Immunology, 2011, 4, 354-364.	6.0	114
106	Role of diet in the development of inflammatory bowel disease. Inflammatory Bowel Diseases, 2010, 16, 137-151.	1.9	199
107	Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nature Genetics, 2010, 42, 1118-1125.	21.4	2,284
108	Serious infections in patients with inflammatory bowel disease receiving antiâ€tumorâ€necrosisâ€factorâ€alpha therapy: An Australian and New Zealand experience. Journal of Gastroenterology and Hepatology (Australia), 2010, 25, 1732-1738.	2.8	78

#	Article	IF	CITATIONS
109	Antiâ€tumour necrosis factorâ€Î± treatment for perianal Crohn's disease in Australia. Medical Journal of Australia, 2010, 192, 375-377.	1.7	1
110	KCNN4 Gene Variant Is Associated With Ileal Crohn's Disease in the Australian and New Zealand Population. American Journal of Gastroenterology, 2010, 105, 2209-2217.	0.4	59
111	Role of small-bowel endoscopy in the management of patients with inflammatory bowel disease: an international OMED–ECCO consensus. Endoscopy, 2009, 41, 618-637.	1.8	319
112	Intestinal barrier dysfunction in inflammatory bowel diseases. Inflammatory Bowel Diseases, 2009, 15, 100-113.	1.9	506
113	Body composition and muscle strength as predictors of bone mineral density in Crohn's disease. Journal of Bone and Mineral Metabolism, 2009, 27, 456-463.	2.7	38
114	The use of indigocarmine spray increases the colonoscopic detection rate of adenomas. Journal of Gastroenterology, 2009, 44, 826-833.	5.1	19
115	Outcomes of salvage therapy for acute severe ulcerative colitis: Cyclosporin versus Infliximab. Inflammatory Bowel Diseases, 2009, 15, S43-S44.	1.9	0
116	Novel NOD2 haplotype strengthens the association between TLR4 Asp299gly and Crohn's disease in an Australian population. Inflammatory Bowel Diseases, 2008, 14, 585-590.	1.9	35
117	Hygiene hypothesis in inflammatory bowel disease: A critical review of the literature. World Journal of Gastroenterology, 2008, 14, 165.	3.3	178
118	The "Fas counterattack―is not an active mode of tumor immune evasion in colorectal cancer with high-level microsatellite instability. Human Pathology, 2008, 39, 243-250.	2.0	21
119	ACE inhibitors and angiotensin II receptor antagonists in Crohn's disease management. Expert Review of Gastroenterology and Hepatology, 2008, 2, 645-651.	3.0	18
120	ATG16L1 T300A Shows Strong Associations With Disease Subgroups in a Large Australian IBD Population: Further Support for Significant Disease Heterogeneity. American Journal of Gastroenterology, 2008, 103, 2519-2526.	0.4	79
121	Reduced Â-defensin expression is associated with inflammation and not NOD2 mutation status in ileal Crohn's disease. Gut, 2008, 57, 903-910.	12.1	211
122	How useful are biomarkers for the prediction of short-term relapse in patients with Crohn's disease?. Nature Reviews Gastroenterology & Hepatology, 2007, 4, 72-73.	1.7	0
123	Two-Year Combination Antibiotic Therapy With Clarithromycin, Rifabutin, and Clofazimine for Crohn's Disease. Gastroenterology, 2007, 132, 2313-2319.	1.3	339
124	Response and remission are associated with improved quality of life, employment and disability status, hours worked, and productivity of patients with ulcerative colitis. Inflammatory Bowel Diseases, 2007, 13, 1135-1140.	1.9	88
125	Tumor necrosis factor-? haplotype is strongly associated with bone mineral density in patients with Crohn's disease. Journal of Gastroenterology and Hepatology (Australia), 2007, 22, 913-919.	2.8	5
126	Relationship between disease severity, quality of life and health-care resource use in a cross-section of Australian patients with Crohn's disease. Journal of Gastroenterology and Hepatology (Australia), 2007, 22, 1306-1312.	2.8	53

#	Article	IF	CITATIONS
127	Clinically active Crohn's disease in the presence of a low C-reactive protein. Scandinavian Journal of Gastroenterology, 2006, 41, 306-311.	1.5	110
128	CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, for steroid-dependent Crohn's disease: a randomized, double-blind, placebo-controlled trial. Alimentary Pharmacology and Therapeutics, 2006, 23, 617-628.	3.7	43
129	Comparison of the efficacy and safety of Eudragit-L-coated mesalazine tablets with ethylcellulose-coated mesalazine tablets in patients with mild to moderately active ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2006, 23, 1017-1026.	3.7	43
130	Angiotensinogen and transforming growth factor Â1: novel genes in the pathogenesis of Crohn's disease. Journal of Medical Genetics, 2006, 43, e51-e51.	3.2	28
131	Associations between NOD2/CARD15 genotype and phenotype in Crohn's disease-Are we there yet. World Journal of Gastroenterology, 2006, 12, 7097.	3.3	47
132	The IBD International Genetics Consortium Provides Further Evidence for Linkage to IBD4 and Shows Gene-Environment Interaction. Inflammatory Bowel Diseases, 2005, 11, 1-7.	1.9	57
133	Bone Loss in Crohn's Disease: Exercise As a Potential Countermeasure. Inflammatory Bowel Diseases, 2005, 11, 1108-1118.	1.9	32
134	Will worms really cure Crohn's disease?. Gut, 2005, 54, 6-8.	12.1	19
135	TNFÂ and IL10 SNPs act together to predict disease behaviour in Crohn's disease. Journal of Medical Genetics, 2005, 42, 523-528.	3.2	56
136	Does the Use of Indigocarmine Spray Increase the Colonoscopic Detection Rate of Advanced Adenomas?. Gastrointestinal Endoscopy, 2005, 61, AB265.	1.0	0
137	CDP571, a humanised monoclonal antibody to tumour necrosis factor Â, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial. Gut, 2004, 53, 1485-1493.	12.1	144
138	Epidemiology of appendicectomy in primary sclerosing cholangitis and ulcerative colitis: its influence on the clinical behaviour of these diseases. Gut, 2004, 53, 973-979.	12.1	70
139	CCR5-Δ32 mutation is strongly associated with primary sclerosing cholangitis. Genes and Immunity, 2004, 5, 444-450.	4.1	66
140	The Use of Indigocarmine Spray Increases the Colonoscopic Detection Rate of Flat Adenomas and Large Sessile Hyperplastic Polyps. Gastrointestinal Endoscopy, 2004, 59, P96.	1.0	2
141	Can Capsule Endoscopy Help Differentiate the Aetiology of Indeterminate Colitis?. Gastrointestinal Endoscopy, 2004, 59, P177.	1.0	13
142	Fas ligand and tumour counter-attack in colorectal cancer stratified according to microsatellite instability status. Journal of Pathology, 2003, 201, 46-54.	4.5	15
143	NOD2 Gene mutations are associated with different clinical phenotypes in patients with Crohn disease. Gastroenterology, 2003, 124, A376.	1.3	0
144	A randomized, placebo-controlled trial of CDP571, a humanized monoclonal antibody to TNF-α, in patients with moderate to severe Crohn's disease. Gastroenterology, 2003, 124, A61.	1.3	14

#	Article	IF	CITATIONS
145	Protective role of appendicectomy on onset and severity of ulcerative colitis and Crohn's disease. Gut, 2002, 51, 808-813.	12.1	171
146	Early Australian experience with infliximab, a chimeric antibody against tumour necrosis factor-alpha, in the treatment of Crohn's disease: is its efficacy augmented by steroid-sparing immunosuppressive therapy?. Internal Medicine Journal, 2001, 31, 146-150.	0.8	48
147	Chronic narcotic use in inflammatory bowel disease patients: Prevalence and clinical characteristics. Journal of Gastroenterology and Hepatology (Australia), 2001, 16, 1235-1238.	2.8	83
148	Tumour infiltrating lymphocytes and apoptosis are independent features in colorectal cancer stratified according to microsatellite instability status. Gut, 2001, 48, 360-366.	12.1	163
149	A randomised multicentre comparison of pantoprazole quadruple and triple therapies versus bismuth triple therapy in H. pylori positive, endoscopy negative dyspepsia. Gastroenterology, 2000, 118, A879.	1.3	4
150	Mycophenolate mofetil in IBD patients. Lancet, The, 1999, 354, 1386-1387.	13.7	11
151	Treatment of steroid refractory inflammatory bowel disease (IBD) with mycophenolate mofetil (MMF). Australian and New Zealand Journal of Medicine, 1998, 28, 344-345.	0.5	27
152	The significance of pANCA in inflammatory bowel disease. Journal of Gastroenterology and Hepatology (Australia), 1998, 13, 863-864.	2.8	4
153	Reciprocal relationship between the tumor suppressors p53 and BAX in primary colorectal cancers. Oncogene, 1998, 17, 2003-2008.	5.9	57
154	Morphology of sporadic colorectal cancer with DNA replication errors. Gut, 1998, 42, 673-679.	12.1	422
155	3 Ulcerative colitis: an immunological disease?. Bailliere's Clinical Gastroenterology, 1997, 11, 35-52.	0.9	11
156	Cytokine gene transcription of human colonic intraepithelial lymphocytes costimulated with epithelial cells bearing HLA-DR and its inhibition by 5-aminosalicylic acid. Journal of Clinical Immunology, 1996, 16, 237-241.	3.8	9
157	10 Cytokines and inflammatory bowel disease. Bailliere's Clinical Gastroenterology, 1996, 10, 151-164.	0.9	47
158	Appendectomy and Tonsillectomy in Patients with Inflammatory Bowel Disease. Journal of Clinical Gastroenterology, 1995, 21, 283-286.	2.2	78
159	Cytokine gene expression in HIV-infected intestinal mucosa. Aids, 1994, 8, 1569-1576.	2.2	56